A novel, efficient delivery system for iron (Fe 2+ ) was developed using the alginate biopolymer.
Introduction 1
Iron deficiency has become the most common nutritional deficiency today (Horton & Ross, 2 2003) .Since the body requires iron to synthesize its oxygen transport proteins in particular, 3 hemoglobin and myoglobin (Abbaspour, et al., 2014) , iron deficiency often leads to anemia. Iron 4 deficiency results from insufficient intake of iron from diet and poor utilization of iron from 5 ingested food or a combination of both factors (Gaucheron, 2000) . The only proven way to lessen 6 this issue is to increase iron intake, either by providing medicinal iron (supplementation) or by 7 adding iron into the diet (fortification), basically to food staples (such as wheat and maize flour) 8 or condiments (such as soy sauce, fish sauce, sugar and salt) (Cook & Reusser, 1983) . Both these 9 approaches heavily utilize ferrous based products (Patil, et al., 2012) . In spite of the development 10 of newer oral iron preparations, ferrous sulphate still remains the first line of treatment (Martıńez-11 Navarrete, et al., 2002 ) mainly due to its low cost and high availability (Patil, et al., 2012) .
12
However, the ferrous ion based supplements are not always compliant due to adverse 13 gastrointestinal effects such as nausea, vomiting and gastric distress (Saha, et al., 2007) , hence 14 limiting the benefits of the iron supplementation therapy. In addition, some severe conditions may 15 occur, such as allergic reactions, black and tarry stools, fever and continuing stomach pain (Hosny, 16 et al., 2015) . Further, its variability is very high in iron absorption, thus effecting the bioavailability 17 (Bregman , et al., 2013 ) .
18
Therefore, there is a need for developing a novel, stable system which is able to increase the iron 19 bioavailability. Previous work on encapsulation techniques for the treatment of anemia with nano 20 drug delivery systems reports the use of ferrous sulphate loaded solid lipid nanoparticles (Zariwala, 21 et al., 2013) , (Hosny, et al., 2015) . The prevention of exposure of ferrous directly to the 22 gastrointestinal tract and the slow release property would be advantageous during its oral uptake.
23
Furthermore, the need for high doses of iron to obtain the therapeutic effect can be avoided through 24 slow release, minimizing the side effects associated with conventional oral iron supplements.
25
Encapsulation protects ferrous ions interacting with other materials and prevents the direct contact 26 of ferrous with gastrointestinal lumen, thus reducing the possible adverse effects (Hosny, et al., 27 2015), (Xia & Xu, 2005) . Alginate biopolymer system has promising properties (Sosnik 2014) and 28 is safe to be used as an oral carrier for iron. Alginic acid and sodium alginate have turned out to 29 be the most extensively explored mucoadhesive biomaterial with good cytocompatibility and biocompatibility (Lee & Mooney, 2012) (Sarei, et al., 2013) . One major advantage of using 31 alginate in oral delivery formulations is their property of being in solid like structure at gastric 32 conditions due to the formation of alginic acid. Hence, it protects the encapsulant inside the core 33 (Draget & Taylor, 2011) . Also, alginate beads dissolve under neutral and basic pH values which 34 is more effective in iron delivery since the absorption of iron occurs mainly in the duodenum in 35 which the pH is around 7.0-8.5 (Draget & Taylor, 2011) .
36
In the current study, we have examined the potential of alginate nanoparticles for oral iron delivery.
37
The aim of our study was to formulate alginate nanoparticles to encapsulate ferrous sulphate and 
Preparation of ferrous loaded alginate nanoparticles

47
The nanoparticles were prepared by ionic gelation based on methods described previously (Daemi 48 & Barikani, 2012) . The pH of a 0.3% w/v solution of sodium alginate (40.0 mL) was adjusted to given below (Singhvi & Singh, 2011 ) (Lokhandwala, et al., 2013 alginate lies between 3.4 to 4.4 (Goswami, et al., 2014) , the alginate biopolymer will be present as 157 dissociated carboxylate ions around pH 5 facilitating the efficient crosslinking with calcium ions.
158
Ascorbic acid was used as an antioxidant to protect the ferrous ion against oxidation.
159
A preliminary experiment was carried out to optimise the iron content in the alginate nanoparticles.
160
Thus formulations were prepared with varying iron concentrations (1%, 2% and 3%, w/w alginate)
161
and iron encapsulation efficiencies were determined. The %encapsulation efficiencies were 75%,
162
48% and 30% with the iron concentrations 1%, 2% and 3% w/w alginate respectively. Increased The -OH stretching of hydroxyl of alginate nanoparticles (3340 cm -1 ) had shifted to 3350 cm -1 in the spectrum of ferrous loaded alginate nanoparticles. The position of carboxylate stretching peaks had also changed upon ferrous loading: the asymmetric -COO -stretching vibration at 1580 cm To further evaluate Fe 2+ loading onto alginate nanoparticles (Fig. 2) , thermo gravimetric analysis
180
(TGA) was carried out (Fig. 2) (Egerton, 2009 ). An ionization 194 edge appears at slightly different positions depending on the actual electron structure of a given 195 material (Muller, et al., 1998) . This difference in the onset position, also referred to as the chemical 196 shift, in most cases does not exceed 1eV (Potapov & Schryvers, 2004 asymmetric with a slight shoulder on the high energy side (Aken & Liebscher, 2002 which has a peak maximum around 714 eV (Fig.3 ).While this L3 edge peak has a shifted peak 202 maximum when it is compared with the L3 edge structure obtained for the reference standard
203
(FeSO4), it is at a different position from FeCl3 with the peak maximum at 713.2 eV (Fig. 3) The particle morphology was examined through the TEM and is depicted in Fig.4 . The spherical
212
shape and smooth surfaces of the nanoparticles with no observed aggregation was clearly visible.
213
Dynamic light scattering (DLS) technique was also used to determine the particle size distribution 214 using Zetasizer Nano ZS. The average size of alginate nanoparticles was around 25 ± 9 nm (Table   215 1), indicating their suitability as a delivery system for iron, for smaller nanoparticles are better for 216 solubility and bioavailability.
218
The average zeta potential or the surface charge of the alginate nanoparticles was -36 ± 3 mV and 219 the zeta potential of the ferrous loaded alginate nanoparticles was -38 ± 4 mV. Both values were 220 quite similar. Considering the high surface to volume ratio of the nanoparticles, the negative charge 221 is maintained even after the loading of iron. Another favorable point is that due to the potential of 222 the particles they are sufficiently repelled from each other thus avoiding agglomeration. 
In vitro release studies of ferrous from alginate nanoparticles
224
The in vitro release study of ferrous from ferrous loaded alginate nanoparticles was carried out in 225 different pH media to confirm the ferrous encapsulation, to understand the release mechanism and 226 kinetics and to determine the optimum condition (pH of medium) for releasing ferrous from the 227 nanoparticles. The in vitro release profile of ferrous from the alginate nanocomposite in different 228 pH buffer solutions (pH 7.4, 6 and 2) are shown in Figure 5 . At pH 7.4 and 6, comparable release profiles could be observed. As expected, an initial burst release of ferrous from alginate 230 nanoparticles in both buffer solutions (pH 7.4 and 6) can be observed during 7-8 h, accounting for 231 about 25-30% of ferrous from the total encapsulated amount. The initial burst release of ferrous 232 may be due to the rapid hydration of nanoparticles considering the hydrophilic nature of alginate.
233
Then, it followed a more gradual and sustained release phase for the next 78 h. The total amount 234 of ferrous released from alginate nanoparticles at pH 7.4 buffer solution was around 65% after 96 235 h while it was around 70% at pH 6. The release profile obtained at pH 2 was quite different from 236 those obtained at pH 7.4 and 6. Here, the initial release was low and after 96 h the total release 237 was less than 20%. Higher percentage of ferrous release at pH 7.4 and 6 is a very favorable 238 condition for iron absorption since iron absorption predominantly occurs in the duodenum where 239 the pH is around 6.
240
Drug release kinetic studies were carried out using model dependent methods which describes the 241 drug dissolution profiles and the best model fitting the release behavior of ferrous from alginate 242 nanoparticles at different pH solutions was selected. According to their adjusted R 2 values (Table   243 2), the drug release from mucoadhesive alginate nanoparticles in all three different buffer solutions depending on the concentration gradient (Singhvi & Singh, 2011) . But Higuchi equation is not 250 directly applicable to complex systems such as polymer matrices loaded with drugs which could 251 be subjected to swelling and eroding (Grassi, et al., 2011) whereas Korsmeyer-Peppas model
252
proposed a semi-empirical model in which the drug release is proportional to the sum of two 253 different powers of time which account for the pure diffusivity contribution (Grassi, et al., 254 2011) (Korsmeyer, et al., 1983) . Hence, Korsmeyer-Peppas model best fit with these release studies hydrophilic polymer materials (Keawchaoon & Yoksan, 2011) , (Motwani, et al., 2008) Release of 65-70% ferrous in the intestinal pH of 6 and 7.4 is good for oral delivery formulations.
269
According to Goswami et al, the release of insulin from alginate nanoparticles at pH 1.2 was less 270 than 20% while it was 90% at pH 7.4 because at low gastric pH alginate forms a compact acid-gel 271 structure restricting the release of drug from the matrix and also protecting the drug from harsh 272 environmental conditions (Goswami, et al., 2014) . Another important factor is that the pKa of 273 alginate lies well above 3.4, hence in very highly acidic medium, alginate remains undissociated 274 protecting the encapsulated drug. Further, it is known that the gastric juice medium does not 275 breakdown alginate nanoparticles thus providing the stability to the nanoparticles which makes 276 them a suitable carrier in oral formulations (Goswami, et al., 2014 (Sarmento, et al., 2007) . Smaller Particle size is also a necessity to be orally absorbed through the 284 intestinal mucosa followed by their passage to systemic circulation (Reis, et al., 2007) . In our 285 study, we were able to prepare alginate nanoparticles with sizes around 20-25 nm which may 286 ensure the particle uptake through the intestine. This claim is further supported by the finding of
287
Jani and co-workers who did a study on nanoparticle uptake by the rat gastrointestinal mucosa 288 using different sized particles. They have shown the successful uptake of particles less than 50 nm 289 by small intestine (Jani, et al., 1990 nanoparticles thus provide an attractive delivery system for conventional oral iron therapy.
